A randomized trial (ISS 901) of switching to didanosine versus continued zidovudine after the diagnosis of AIDS

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 12, Issue 5, 1996, Pages 462-469

  Vella, Stefano ^a   Floridia, Marco ^a   Dally, Leonard G ^a   Tomino, Carlo ^a   Fragola, Vincenzo ^a   Weimer, Liliana E ^a   Milazzo, Francesco ^b   Mazzotta, Francesco ^c   Moroni, Mauro ^d   Pastore, Giuseppe ^e   Scalise, Giorgio ^f   Sinicco, Alessandro ^g   Ortona, Luigi ^h   De Rienzo, Bruno ⁱ   Dianzani, Ferdinando ^j  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e UNIVERSITY OF BARI   (Italy)

^f UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^g UNIVERSITY OF TURIN   (Italy)

^h CATHOLIC UNIVERSITY   (Italy)

ⁱ UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^j SAPIENZA UNIVERSITY OF ROME   (Italy)

more..

Author keywords

AIDS; Didanosine; Survival; Zidovudine

Indexed keywords

AMINOTRANSFERASE; AMYLASE; DIDANOSINE; HEMOGLOBIN; URIC ACID; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FOLLOW UP; HUMAN; LYMPHOCYTE COUNT; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PANCREATITIS; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; TREATMENT PLANNING;

HUMAN IMMUNODEFICIENCY VIRUS; PNEUMOCYSTIS CARINII;

EID: 9444292816     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199608150-00004     Document Type: Article

References (24)

1. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebocontrolled trial. N Engl J Med 1987;317:185-91.
2. Vella S, Giuliano M, Pezzotti P, et al. Survival of zidovudine-treated patients with AIDS compared with that of contemporary untreated patients. JAMA 1992;267:1232-6.
3. Buira E, Gatell JM, Mirò JM, et al. Influence of treatment with zidovudine on the long-term survival of AIDS patients. J Acquir Immun Defic Syndr 1992;5:737-42.
4. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med 1990;322: 941-9.
5. Fischl MA, Richman DD, Hansen N, et al. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symtomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. Ann Intern Med 1990;112:727-37.
6. Hamilton JD, Hartigan PM, Simberkoff MS, et al. A controlled trial of early versus late treatment with zidovudine in symtomatic human immunodeficiency virus infection. N Engl J Med 1992;326:437-43.
7. Graham NMH, Zeger SL, Park LP, et al. The effects on survival of early treatment of human immunodeficiency virus infection. N Engl J Med 1992;326:1037-42.
8. Concorde Coordinating Committee: Concorde. MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994;343:871-81.
9. Volberding PA, Lagakos SW, Grimes JM, et al. The duration of zidovudine benefit in persons with asymptomatic HIV infection. JAMA 1994;272:437-42.
10. Rozencweig M, McLaren C, Beltangady M, et al. Overview of Phase I trials of 2′,3′-dideoxyinosine (ddI) conducted on adult patients. Rev Infect Dis 1990;12(Suppl 5):S570-5.
11. De Clerq E. HIV resistance to reverse transcriptase inhibitors. Biochem Pharmacol 1994;47:155-69.
12. Gao WY, Shrisaka T, Johns DG, et al. Differential phosphorylation of azidothymidine, dideoxycytidine and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J Clin Invest 1993;91:2326-33.
13. Katzenstein DA, Winters M, Bubp J, Israelski D, Winger E, Merigan TC. Quantitation of human immunodeficiency virus by culture and polymerase chain reaction in response to didanosine after long-term treatment with zidovudine. J Infect Dis 1994;169:416-9.
14. Mayers DL, Wagner KF, Chung RCY, et al. Virologic response to ddI following prolonged AZT. Xth International Conference on AIDS, Yokohama, August 1994:Vol 2, Abstr 359B.
15. Kahn JO, Lagakos SW, Richman DD, et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. N Engl J Med 1992; 327:581-7.
16. Spruance SL, Pavia AT, Peterson D, et al. Didanosine compared with continuation of zidovudine in HIV-infected patients with signs of clinical deterioration while receiving zidovudine. Ann Intern Med 1994;120:360-8.
17. Portegies P, Enting RH, de Jong MD, et al. AIDS dementia complex and didanosine. Lancet 1994;344:759.
18. Price RW, Brew BJ. The AIDS dementia complex. J Infect Dis 1988;158:1079-83.
19. Pantaleo G, Graziosi C, Demarest JF, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993;362:355-8.
20. Coombs RW, Collier AC, Allain J-P, et al. Plasma viremia in human immunodeficiency virus infection. N Engl J Med 1989;321:1626-31.
21. + T-lymphocyte decline and clinical progression in human immunodeficiency virus type-1 infected individuals. J Virol 1993;67: 1772-7.
22. Tersmette M, De Gooede RYE, Al BJM, et al. Differential syncitium-inducing capacity of Human Immunodeficiency virus isolates: frequent detection of syncitium-inducing isolates in patients with AIDS and AIDS-related complex. J Virol 1988;62:2026-32.
23. 3. Ann Intern Med 1995;123:561-71.
24. ACTG 175. Anti-HIV therapy lowers risk of AIDS, death in patients with intermediate-stage HIV disease. In: NIAID NEWS. Bethesda, MD: Office of Communications, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Sept. 14, 1995.